GenSpera (OTCQB:GNSZ) Media Advisory; "Targeting
thapsigargin towards tumors" Published in Steroids
SAN ANTONIO - August 28, 2014 (Investorideas.com Biotech
Newswire) GenSpera, Inc. (OTCQB:GNSZ),
a leader in developing prodrug therapeutics for the treatment of cancer,
announces the recent publication of the article "Targeting thapsigargin
towards tumors" in the journal Steroids.
The
recent article co-authored by Doan, et al. (see full reference below), reviews
the evolution and development of GenSpera's prodrug technology platform that is
designed to deliver the potent, cytotoxic activity of thapsigargin (from the
plant Thapsia garganica) directly to tumors. These efforts led to the
development of mipsagargin (G-202), which is now in Phase II clinical trials in
liver cancer and brain cancer.
The
article details the discovery and isolation of thapsigargin, the elucidation of
its molecular structure, and determination of its biochemical and pharmacological
activities.
These
efforts revealed the potential utility of thapsigargin as a potent, but
non-selective anti-cancer agent. It was recognized that in order to harness the
profound cytotoxic activity of thapsigargin, one would need to develop a way of
delivering it specifically to tumors in order to avoid side effects.
The
paper also goes on to describe the medicinal chemistry efforts to develop
derivatives of thapsigargin in order to create protease-activated prodrugs that
could be activated only within the tumors. The in vitro and in vivo experiments
led to a number of potentially useful prodrugs directed to the tumor-selective
enzymes PSMA, PSA and hK-2. Mipsagargin is the most developmentally advanced
drug candidate and is activated by the enzyme PSMA, which is found in the blood
vessels of almost all solid tumors.
The
review highlights the drug development success that can be achieved through a
multidisciplinary and multinational collaboration between academic laboratories
and an industrial partner.
Targeting
thapsigargin towards tumors
Steroids,
available online 24 July 2014, Nhu Thi Quynh Doan, Eleonora Sandholdt Paulsen,
Pankaj Sehgal, Jesper Vuust Møller, Poul Nissen, Samuel R. Denmeade, John T.
Isaacs, Craig A. Dionne, Søren Brøgger Christensen
And
(In press: Doan NTQ et al. Targeting thapsigargin towards tumors. Steroids
(2014) http://dx.doi.org/10.1016/j.steroids.2014.07.009)
About GenSpera (GNSZ):
GenSpera's
technology platform combines a powerful, plant-derived cytotoxin (thapsigargin)
with a pro-drug delivery system that provides for the targeted release of drug
candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin
results in cell death irrespective of the rate of cell division, which may
provide an effective approach to kill both fast- and slow-growing cancers.
GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which
is found at high levels in the vasculature of liver and glioblastoma cancers
and in the vasculature of almost all other solid tumors. G-202 is therefore
expected to have potential efficacy in a wide variety of tumor types.
G-202
Phase II clinical trials are underway in hepatocellular carcinoma, glioblastoma
and prostate cancer patients.
Cautionary Statement Regarding Forward
Looking Information
This news
release may contain forward-looking statements. Investors are cautioned that
statements in this press release regarding potential applications of GenSpera’s
technologies constitute forward-looking statements that involve risks and
uncertainties, including, without limitation, risks inherent in the development
and commercialization of potential products, uncertainty of clinical trial
results or regulatory approvals or clearances, need for future capital,
dependence upon collaborators and maintenance of our intellectual property
rights. Actual results may differ materially from the results anticipated in
these forward-looking statements. Additional information on potential factors
that could affect our results and other risks and uncertainties will be
detailed from time to time in GenSpera’s periodic reports filed with the
Securities and Exchange Commission.
Company:
Craig Dionne,
PhD, CEO
GenSpera,
Inc. (210) 479-8112
Investors:
Steve Gersten
Capital Markets Group
Steve@CapMarketsGroup.com
+1-813-926-8920
Media:
Dawn Van Zant
(800) 665 0411
Disclaimer/Disclosure:
Investorideas.com newswire is a third party publisher of news and research as
well as creates original content as a news source. Original content created by
investorideas is protected by copyright laws other than syndication rights.
Investorideas is a news source on Google news and Linkedintoday plus hundreds
of syndication partners. Our site does not make recommendations for purchases
or sale of stocks or products. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. All investment
involves risk and possible loss of investment. This site is currently
compensated by featured companies, news submissions, content marketing and
online advertising. Contact each company directly for press release questions.
Disclosure is posted on each release if required but otherwise the news was not
compensated for and is published for the sole interest of our readers. More
disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure:
Genspera (GNSZ) has engaged Investor Ideas for PR and news publication
effective June 18, 2014 (compensation of five thousand per month and average of
eleven thousand five hundred 144 shares per month)
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an
Investorideas.com Member and access our 14 online stock directories 24/7 –biotech,
mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/
No comments:
Post a Comment